The clinicopathologic significance of FOXC1 in BRCA-mutant breast cancer.

被引：0
|
作者：
Choi, Michael Phillip
Cui, Xiaojiang
Dadmanesh, Farnaz
Liles, Georgia
Zhang, Xiao
Karlan, Beth
Glullano, Armando E.
Amersi, Farin F.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1556
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The FOXC1/FBP1 signaling axispromotes tumorigenicity by enhancing the Warburg effect in colorectal cancer.
    Li, Dawei
    Li, Qingguo
    Cai, Sanjun
    Xie, Keping
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Retrospective analysis of efficacy of immune checkpoint inhibitors in BRCA-mutant non-small cell lung cancer.
    Chen, Shaomu
    Li, Si
    Chen, Dongsheng
    Xiao, Mingzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
    Kim, Chorong
    Kim, Danbee
    Lee, Da sol
    Lee, Seonmin
    Yoo, Changhoon
    Kim, Kyu-pyo
    ANTICANCER RESEARCH, 2023, 43 (12) : 5523 - 5533
  • [24] BRCA1 and epigenetics in breast cancer.
    Birgisdottir, V
    Bodvarsdottir, SK
    Hilmarsdottir, H
    Jonasson, JG
    Eyfjord, J
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 336 - 336
  • [25] FOXC1: an emerging marker and therapeutic target for cancer
    B Han
    N Bhowmick
    Y Qu
    S Chung
    A E Giuliano
    X Cui
    Oncogene, 2017, 36 : 3957 - 3963
  • [26] FOXC1 is associated with estrogen receptor and affects sensitivity of tamoxifen treatment in breast cancer
    Wang, Jin-hua
    Xu, Ya-li
    Chen, Xiu-ping
    Li, Li
    Wang, Lin
    Yao, Ru
    Sun, Qiang
    Du, Guan-hua
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (07) : 1079 - 1080
  • [27] Clinicopathologic Features of BRCA-Mutant NSCLC Patients Characterized by Comprehensive Histologic Subtyping and Comprehensive Genomic Profiling
    Suh, James
    Johnson, Adrienne
    Gay, Laurie
    Frampton, Garrett M.
    Garland, Linda
    Ali, Siraj
    Miller, Vincent A.
    Stephens, Philip M.
    Ross, Jeffrey S.
    Elvin, Julia A.
    LABORATORY INVESTIGATION, 2018, 98 : 751 - 751
  • [28] Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives
    Li, Xin Yu
    Chen, Jia Qi
    Aisa, Adilai
    Ding, Yu Wei
    Zhang, Ding
    Yuan, Ying
    JOURNAL OF DIGESTIVE DISEASES, 2023, 24 (02) : 85 - 97
  • [29] FOXC1: an emerging marker and therapeutic target for cancer
    Han, B.
    Bhowmick, N.
    Qu, Y.
    Chung, S.
    Giuliano, A. E.
    Cui, X.
    ONCOGENE, 2017, 36 (28) : 3957 - 3963
  • [30] BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers
    Tkocz, D.
    Crawford, N. T.
    Buckley, N. E.
    Berry, F. B.
    Kennedy, R. D.
    Gorski, J. J.
    Harkin, D. P.
    Mullan, P. B.
    ONCOGENE, 2012, 31 (32) : 3667 - 3678
12345